ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use

Neena S. Abraham; Mark A. Hlatky; Elliott M. Antman; Deepak L. Bhatt; David J. Bjorkman; Craig B. Clark; Curt D. Furberg; David A. Johnson; Charles J. Kahi; Loren Laine; Kenneth W. Mahaffey; Eamonn M. Quigley; James Scheiman; Laurence S. Sperling; Gordon F. Tomaselli

doi:10.1038/ajg.2010.445

ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use

Neena S. Abraham, Mark A. Hlatky, Elliott M. Antman, Deepak L. Bhatt, David J. Bjorkman, Craig B. Clark, Curt D. Furberg, David A. Johnson, Charles J. Kahi, Loren Laine, Kenneth W. Mahaffey, Eamonn M. Quigley, James Scheiman, Laurence S. Sperling, Gordon F. Tomaselli

Research output: Contribution to journal › Review article › peer-review

148 Scopus citations

Original language	English (US)
Pages (from-to)	2533-2549
Number of pages	17
Journal	American Journal of Gastroenterology
Volume	105
Issue number	12
DOIs	https://doi.org/10.1038/ajg.2010.445
State	Published - Dec 2010

Keywords

ACCF Expert Consensus Document antiplatelet drugs
aspirin
gastrointestinal hemorrhage
platelet aggregation inhibitors
proton pump inhibitors
thienopyridine

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1038/ajg.2010.445

Cite this

Abraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., Mahaffey, K. W., Quigley, E. M., Scheiman, J., Sperling, L. S., & Tomaselli, G. F. (2010). ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. American Journal of Gastroenterology, 105(12), 2533-2549. https://doi.org/10.1038/ajg.2010.445

ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. / Abraham, Neena S.; Hlatky, Mark A.; Antman, Elliott M. et al.
In: American Journal of Gastroenterology, Vol. 105, No. 12, 12.2010, p. 2533-2549.

Research output: Contribution to journal › Review article › peer-review

Abraham, NS, Hlatky, MA, Antman, EM, Bhatt, DL, Bjorkman, DJ, Clark, CB, Furberg, CD, Johnson, DA, Kahi, CJ, Laine, L, Mahaffey, KW, Quigley, EM, Scheiman, J, Sperling, LS & Tomaselli, GF 2010, 'ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use', American Journal of Gastroenterology, vol. 105, no. 12, pp. 2533-2549. https://doi.org/10.1038/ajg.2010.445

Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB et al. ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. American Journal of Gastroenterology. 2010 Dec;105(12):2533-2549. doi: 10.1038/ajg.2010.445

Abraham, Neena S. ; Hlatky, Mark A. ; Antman, Elliott M. et al. / ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines : A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. In: American Journal of Gastroenterology. 2010 ; Vol. 105, No. 12. pp. 2533-2549.

@article{3e8192bee2cf44539fbfe0c3af0bb3eb,

title = "ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use",

keywords = "ACCF Expert Consensus Document antiplatelet drugs, aspirin, gastrointestinal hemorrhage, platelet aggregation inhibitors, proton pump inhibitors, thienopyridine",

author = "Abraham, {Neena S.} and Hlatky, {Mark A.} and Antman, {Elliott M.} and Bhatt, {Deepak L.} and Bjorkman, {David J.} and Clark, {Craig B.} and Furberg, {Curt D.} and Johnson, {David A.} and Kahi, {Charles J.} and Loren Laine and Mahaffey, {Kenneth W.} and Quigley, {Eamonn M.} and James Scheiman and Sperling, {Laurence S.} and Tomaselli, {Gordon F.}",

note = "Funding Information: Peer Reviewer Representation Consultant Speaker Ownership/ Partnership/ Principal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Eric R. Bates Official Reviewer—AHA Official Reviewer—ACCF Task Force on Clinical Expert Consensus Documents • Bristol-Myers Squibb • Daiichi Sankyo • Eli Lilly • Momenta • Novartis • Sanofi-Aventis • Takeda None None None None None James H. Chesebro Official Reviewer—AHA None None None None None None Philip O. Katz Official Reviewer—ACG • Eisai • Novartis • Takeda • XenoPort None None None • ACG President None Richard J. Kovacs Official Reviewer—ACCF Board of Trustees • Abbott Laboratories • Biomedical Systems • Cook–Med Institute * • ECG Scanning Services * • Eli Lilly * • Endocyte • Essentialis • XenoPort None None None None None John F. Robb Official Reviewer—ACC Board of Governors None None None None None None Jeffrey L. Anderson Content Reviewer— ACCF/AHA UA Guideline • Sanofi/Bristol-Myers Squibb None None • AstraZeneca (DSMB) • Gilead Pharma (DSMB) • Toshiba None • Defendant, management of cardiopulmonary arrest postop, 2010 • Defendant, stroke after ablation for AF, 2010 John G. Byrne Content Reviewer— ACC Surgeon Scientific Council • Edwards Lifesciences None None None None None Jose G. Diez Content Reviewer—ACC Interventional Scientific Council • Sanofi-Aventis None None None None None L. David Hillis Content Reviewer— ACCF/AHA CABG Guideline None None None None None None Glenn N. Levine Content Reviewer—ACCF/AHA PCI Guideline None None None None None • Defendant, patient nonresponsive after noncardiac surgery, 2010 Patrick T. O'Gara Content Reviewer—ACCF/AHA STEMI Guideline None None None • Lantheus Medical Imaging • National Institutes of Health * • AHA (Scientific Advisory and Coordinating Committee; Editor-in-Chief, Heart Insight magazine) None This table represents the relationships with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACG, American College of Gastroenterology; AF, atrial fibrillation; AHA, American Heart Association; CABG, coronary artery bypass graft; DSMB, Data Safety Monitoring Board; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; and UA, unstable angina. * Significant relationship. ",

year = "2010",

month = dec,

doi = "10.1038/ajg.2010.445",

language = "English (US)",

volume = "105",

pages = "2533--2549",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "12",

}

TY - JOUR

T1 - ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines

T2 - A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use

AU - Abraham, Neena S.

AU - Hlatky, Mark A.

AU - Antman, Elliott M.

AU - Bhatt, Deepak L.

AU - Bjorkman, David J.

AU - Clark, Craig B.

AU - Furberg, Curt D.

AU - Johnson, David A.

AU - Kahi, Charles J.

AU - Laine, Loren

AU - Mahaffey, Kenneth W.

AU - Quigley, Eamonn M.

AU - Scheiman, James

AU - Sperling, Laurence S.

AU - Tomaselli, Gordon F.

N1 - Funding Information: Peer Reviewer Representation Consultant Speaker Ownership/ Partnership/ Principal Research Institutional, Organizational, or Other Financial Benefit Expert Witness Eric R. Bates Official Reviewer—AHA Official Reviewer—ACCF Task Force on Clinical Expert Consensus Documents • Bristol-Myers Squibb • Daiichi Sankyo • Eli Lilly • Momenta • Novartis • Sanofi-Aventis • Takeda None None None None None James H. Chesebro Official Reviewer—AHA None None None None None None Philip O. Katz Official Reviewer—ACG • Eisai • Novartis • Takeda • XenoPort None None None • ACG President None Richard J. Kovacs Official Reviewer—ACCF Board of Trustees • Abbott Laboratories • Biomedical Systems • Cook–Med Institute * • ECG Scanning Services * • Eli Lilly * • Endocyte • Essentialis • XenoPort None None None None None John F. Robb Official Reviewer—ACC Board of Governors None None None None None None Jeffrey L. Anderson Content Reviewer— ACCF/AHA UA Guideline • Sanofi/Bristol-Myers Squibb None None • AstraZeneca (DSMB) • Gilead Pharma (DSMB) • Toshiba None • Defendant, management of cardiopulmonary arrest postop, 2010 • Defendant, stroke after ablation for AF, 2010 John G. Byrne Content Reviewer— ACC Surgeon Scientific Council • Edwards Lifesciences None None None None None Jose G. Diez Content Reviewer—ACC Interventional Scientific Council • Sanofi-Aventis None None None None None L. David Hillis Content Reviewer— ACCF/AHA CABG Guideline None None None None None None Glenn N. Levine Content Reviewer—ACCF/AHA PCI Guideline None None None None None • Defendant, patient nonresponsive after noncardiac surgery, 2010 Patrick T. O'Gara Content Reviewer—ACCF/AHA STEMI Guideline None None None • Lantheus Medical Imaging • National Institutes of Health * • AHA (Scientific Advisory and Coordinating Committee; Editor-in-Chief, Heart Insight magazine) None This table represents the relationships with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily reflect relationships with industry at the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, or ownership of $10,000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person's gross income for the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACG, American College of Gastroenterology; AF, atrial fibrillation; AHA, American Heart Association; CABG, coronary artery bypass graft; DSMB, Data Safety Monitoring Board; PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction; and UA, unstable angina. * Significant relationship.

PY - 2010/12

Y1 - 2010/12

KW - ACCF Expert Consensus Document antiplatelet drugs

KW - aspirin

KW - gastrointestinal hemorrhage

KW - platelet aggregation inhibitors

KW - proton pump inhibitors

KW - thienopyridine

UR - http://www.scopus.com/inward/record.url?scp=78649823909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649823909&partnerID=8YFLogxK

U2 - 10.1038/ajg.2010.445

DO - 10.1038/ajg.2010.445

M3 - Review article

C2 - 21131924

AN - SCOPUS:78649823909

SN - 0002-9270

VL - 105

SP - 2533

EP - 2549

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 12

ER -

ACCF/ACG/AHA 2010 expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: A focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this